How Oak Longevity works, what the headline price means, and what remains unresolved
Oak Longevity is the current consumer brand for a cash-pay telehealth platform. The approved affiliate relationship is labeled Oak Weight Loss, but the issued tracking link opens the Oak Longevity intake. Oak's website also promotes longevity, men's health, and women's health services. This review concentrates on the current weight-loss program because that is the affiliate campaign and the best-supported in-scope offering.
The legal operator is not presented consistently. The newest agreement on the terms page names Oaklovesyou LLC. Earlier content on the same page names Oak Longevity Holdings Corp., Leaf Longevity Holdings Corp. DBA Oak Longevity, and Oak Longevity Corp. The privacy page repeats several entities and includes an older template that identifies the country as Canada even though the care service is marketed in the United States. These drafting problems do not prove that the service is illegitimate, but they make it harder to know which entity controls a transaction and policy.
Oak says it provides a technology and administrative platform rather than medical care. Independent physicians or nurse practitioners contracted through medical-group partners evaluate the health questionnaire and decide whether treatment is appropriate. The site advertises board-certified and obesity-certified clinicians, but no current public clinician roster, medical-group name, or state-license list was found. Patients should verify the actual assigned clinician rather than relying on a general credential claim.
The weight-loss page lists compounded semaglutide and compounded tirzepatide as weekly injections. It says either medication may be formulated with vitamin B6 or B12 when appropriate. Those vitamins are formulation details and do not create separate medication identities. The page also mentions oral tablets, sublingual drops, and peptides without naming one active ingredient for every non-injectable option, so those products remain editorial details rather than comparison cards.
The dedicated weight-loss page says programs start at $190 per month. The homepage separately says Oak programs start at $119 per month. The lower figure is not assigned to weight loss, semaglutide, tirzepatide, or any other specific program. For a weight-loss comparison, $190 is the more relevant headline, but it still cannot be placed on either medication card because Oak does not identify which drug, dose, formulation, billing term, or commitment receives it.
Oak also does not publish a complete initial-charge or renewal table. The terms say many prescriptions are configured as recurring subscriptions and that the fee may change with dose, prescription, or product form. A low starter price therefore may not predict the ongoing cost. Before entering payment details, patients should ask for the exact amount due today, every scheduled charge, the refill cadence, the price at higher doses, and the procedure for declining a price change.
The fee language is internally inconsistent. The homepage, weight-loss page, and intake say there are no hidden or monthly membership fees. The terms say Oak charges a membership fee for access to a provider consultation and other services, with $20 attributed to an asynchronous visit or $40 to a synchronous visit. The terms also say fees charged by health care providers or pharmacies may be additional. Until Oak reconciles these statements, the $190 headline should not be treated as a guaranteed all-in price.
The onboarding path is simple. Oak advertises a short online health form, no routine video call, and clinician review within hours or the same day. Treatment is not guaranteed, and a clinician may request more information or decide that a GLP-1 is not appropriate. The weight-loss page excludes people under eighteen, people who are pregnant or nursing, and some applicants with a body mass index below twenty-two and no qualifying health history.
Oak does not name a default dispensing pharmacy. Its terms refer to the Oak Pharmacy Network and authorize the assigned clinician to send a prescription into that network. The weight-loss page says every batch is tested by certified third-party laboratories, but it does not identify the pharmacy, laboratory, certificate, assay, or batch record. Patients should request the pharmacy name and state license, exact active ingredient, concentration, additives, dose in milligrams, syringe-unit instructions, beyond-use date, storage range, and testing documentation for the product actually dispensed.
Compounded semaglutide and tirzepatide products are not FDA approved. Oak acknowledges this on its homepage, but it also uses phrases such as same active ingredient, same science, and designed to support the same clinical outcomes. FDA lists claims that a compounded drug is the same as an FDA-approved drug as a telehealth warning sign. Sharing an active ingredient does not establish that a compounded formulation has the same quality, dose accuracy, stability, bioavailability, or clinical evidence as an approved product.
Current FDA policy also matters to the business model. Semaglutide and tirzepatide are not on the national shortage list, and the broad shortage-related enforcement periods have ended. Patient-specific compounding may still qualify under federal law when the statutory conditions are met, but routine essentially-copy production is restricted. Adding B6 or B12 does not automatically establish a legally significant difference for every patient. The prescriber and pharmacy should be able to explain the individualized clinical rationale.
Shipping is advertised as free, tracked, and available within days, with same-day shipment also stated on the weight-loss page. Oak does not publish one guaranteed processing window, carrier-delay procedure, temperature-excursion rule, or replacement policy. The latest terms say medication sent through the Oak Pharmacy Network may not use child-resistant packaging. Patients with children or other household risks should plan secure storage before delivery.
Cancellation is available through the account, and an older retained section says Oak aims to act within twenty-four hours. That does not stop every pending shipment. Paid refills close to dispatch may still be sent, and an order becomes nonrefundable once a clinician approves treatment and the prescription is sent to the pharmacy or fulfillment partner. Carrier refusal, rerouting, or account cancellation after that cutoff does not create a refund under the stated policy.
Oak does not submit commercial-insurance, Medicare, or Medicaid claims. The terms place responsibility for HSA or FSA eligibility on the patient. A separate Oak lab business sells one-time, monthly, and quarterly at-home testing plans, but the weight-loss page does not say that one of those plans is required or included. Patients should confirm whether baseline or follow-up labs are clinically required and what they cost before starting.
Availability is also incomplete. One older retained terms section says Oak serves forty-five states, while the later agreement says availability depends on the state and the type of service. No current public state list was found. Because clinician licensure, pharmacy shipping, and compounded-drug rules vary, patients should confirm all three for their own state before authorizing payment.
- The $190 weight-loss headline is not medication-specific, so neither semaglutide nor tirzepatide receives a comparison price.
- No-membership-fee marketing conflicts with membership and professional-service fee language in the terms.
- Clinician, medical-group, pharmacy, state availability, and product-testing details must be verified after intake.